GAL3 Protein Expression is Related to Clinical Features of Prolactin-Secreting Pituitary Microadenoma and Predicts its Recurrence after Surgical Treatment
Background: Previous in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of Gal-3 expression with the clinical feature and prognosis of pituitary tumor in a clinical setting remains unknown. Methods: We enrolled 220 patie...
Saved in:
Published in | Cellular physiology and biochemistry Vol. 33; no. 4; pp. 1026 - 1035 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Basel, Switzerland
Cell Physiol Biochem Press GmbH & Co KG
01.01.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background: Previous in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of Gal-3 expression with the clinical feature and prognosis of pituitary tumor in a clinical setting remains unknown. Methods: We enrolled 220 patients with prolactin-secreting pituitary adenomas (PA) who previously had transsphenoidal pituitary surgery. The Gal-3 expression was detected in the patients' PA samples using immunohistochemistry and those patients were followed up. A prolactin-secreting PA cell line, the MMQ cell line, was used to study the in vitro effect of Gal-3 on proliferation, migration and invasion of PA cells using small interfering RNA (siRNA) transfecton technique. The in vivo tumorgenesis in nude mice was also studied. Results: We found that Gal-3 expression was not related to age and sex, but positively associated with tumor invasion (P<0.001), tumor sizes (P<0.001) and pre-operative prolactin levels (P<0.001). The multivariate Cox analysis showed that the Gal-3 expression was closely associated with the recurrence of PA after the surgical treatment (HR =3.15, P=0.002). The in vitro studies showed that Gal-3 knock-down by the siRNA technique significantly inhibited the proliferation, migration and invasion ability of the MMQ cells, whereas Gal-3 siRNA transfection induced apoptosis of the MMQ cells. The in vivo tumorgenesis assay showed that Gal-3 siRNA transfection significantly inhibited the tumor volume in vivo compared to transfection of the control siRNA (P<0.001). Conclusion: Gal-3 regulates proliferation, apoptosis, migration and invasion of the MMQ cells. Gal-3 may be used as a tissue marker to evaluate the clinical feature and prognosis of PA patients. |
---|---|
AbstractList | Background: Previous in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of Gal-3 expression with the clinical feature and prognosis of pituitary tumor in a clinical setting remains unknown. Methods: We enrolled 220 patients with prolactin-secreting pituitary adenomas (PA) who previously had transsphenoidal pituitary surgery. The Gal-3 expression was detected in the patients' PA samples using immunohistochemistry and those patients were followed up. A prolactin-secreting PA cell line, the MMQ cell line, was used to study the in vitro effect of Gal-3 on proliferation, migration and invasion of PA cells using small interfering RNA (siRNA) transfecton technique. The in vivo tumorgenesis in nude mice was also studied. Results: We found that Gal-3 expression was not related to age and sex, but positively associated with tumor invasion (P<0.001), tumor sizes (P<0.001) and pre-operative prolactin levels (P<0.001). The multivariate Cox analysis showed that the Gal-3 expression was closely associated with the recurrence of PA after the surgical treatment (HR =3.15, P=0.002). The in vitro studies showed that Gal-3 knock-down by the siRNA technique significantly inhibited the proliferation, migration and invasion ability of the MMQ cells, whereas Gal-3 siRNA transfection induced apoptosis of the MMQ cells. The in vivo tumorgenesis assay showed that Gal-3 siRNA transfection significantly inhibited the tumor volume in vivo compared to transfection of the control siRNA (P<0.001). Conclusion: Gal-3 regulates proliferation, apoptosis, migration and invasion of the MMQ cells. Gal-3 may be used as a tissue marker to evaluate the clinical feature and prognosis of PA patients. Background: Previous in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of Gal-3 expression with the clinical feature and prognosis of pituitary tumor in a clinical setting remains unknown. Methods: We enrolled 220 patients with prolactin-secreting pituitary adenomas (PA) who previously had transsphenoidal pituitary surgery. The Gal-3 expression was detected in the patients' PA samples using immunohistochemistry and those patients were followed up. A prolactin-secreting PA cell line, the MMQ cell line, was used to study the in vitro effect of Gal-3 on proliferation, migration and invasion of PA cells using small interfering RNA (siRNA) transfecton technique. The in vivo tumorgenesis in nude mice was also studied. Results: We found that Gal-3 expression was not related to age and sex, but positively associated with tumor invasion (Pin vitro studies showed that Gal-3 knock-down by the siRNA technique significantly inhibited the proliferation, migration and invasion ability of the MMQ cells, whereas Gal-3 siRNA transfection induced apoptosis of the MMQ cells. The in vivo tumorgenesis assay showed that Gal-3 siRNA transfection significantly inhibited the tumor volume in vivo compared to transfection of the control siRNA (PConclusion: Gal-3 regulates proliferation, apoptosis, migration and invasion of the MMQ cells. Gal-3 may be used as a tissue marker to evaluate the clinical feature and prognosis of PA patients. Previous in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of Gal-3 expression with the clinical feature and prognosis of pituitary tumor in a clinical setting remains unknown.BACKGROUNDPrevious in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of Gal-3 expression with the clinical feature and prognosis of pituitary tumor in a clinical setting remains unknown.We enrolled 220 patients with prolactin-secreting pituitary adenomas (PA) who previously had transsphenoidal pituitary surgery. The Gal-3 expression was detected in the patients' PA samples using immunohistochemistry and those patients were followed up. A prolactin-secreting PA cell line, the MMQ cell line, was used to study the in vitro effect of Gal-3 on proliferation, migration and invasion of PA cells using small interfering RNA (siRNA) transfecton technique. The in vivo tumorgenesis in nude mice was also studied.METHODSWe enrolled 220 patients with prolactin-secreting pituitary adenomas (PA) who previously had transsphenoidal pituitary surgery. The Gal-3 expression was detected in the patients' PA samples using immunohistochemistry and those patients were followed up. A prolactin-secreting PA cell line, the MMQ cell line, was used to study the in vitro effect of Gal-3 on proliferation, migration and invasion of PA cells using small interfering RNA (siRNA) transfecton technique. The in vivo tumorgenesis in nude mice was also studied.We found that Gal-3 expression was not related to age and sex, but positively associated with tumor invasion (P<0.001), tumor sizes (P<0.001) and pre-operative prolactin levels (P<0.001). The multivariate Cox analysis showed that the Gal-3 expression was closely associated with the recurrence of PA after the surgical treatment (HR =3.15, P=0.002). The in vitro studies showed that Gal-3 knock-down by the siRNA technique significantly inhibited the proliferation, migration and invasion ability of the MMQ cells, whereas Gal-3 siRNA transfection induced apoptosis of the MMQ cells. The in vivo tumorgenesis assay showed that Gal-3 siRNA transfection significantly inhibited the tumor volume in vivo compared to transfection of the control siRNA (P<0.001).RESULTSWe found that Gal-3 expression was not related to age and sex, but positively associated with tumor invasion (P<0.001), tumor sizes (P<0.001) and pre-operative prolactin levels (P<0.001). The multivariate Cox analysis showed that the Gal-3 expression was closely associated with the recurrence of PA after the surgical treatment (HR =3.15, P=0.002). The in vitro studies showed that Gal-3 knock-down by the siRNA technique significantly inhibited the proliferation, migration and invasion ability of the MMQ cells, whereas Gal-3 siRNA transfection induced apoptosis of the MMQ cells. The in vivo tumorgenesis assay showed that Gal-3 siRNA transfection significantly inhibited the tumor volume in vivo compared to transfection of the control siRNA (P<0.001).Gal-3 regulates proliferation, apoptosis, migration and invasion of the MMQ cells. Gal-3 may be used as a tissue marker to evaluate the clinical feature and prognosis of PA patients.CONCLUSIONGal-3 regulates proliferation, apoptosis, migration and invasion of the MMQ cells. Gal-3 may be used as a tissue marker to evaluate the clinical feature and prognosis of PA patients. Previous in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of Gal-3 expression with the clinical feature and prognosis of pituitary tumor in a clinical setting remains unknown. We enrolled 220 patients with prolactin-secreting pituitary adenomas (PA) who previously had transsphenoidal pituitary surgery. The Gal-3 expression was detected in the patients' PA samples using immunohistochemistry and those patients were followed up. A prolactin-secreting PA cell line, the MMQ cell line, was used to study the in vitro effect of Gal-3 on proliferation, migration and invasion of PA cells using small interfering RNA (siRNA) transfecton technique. The in vivo tumorgenesis in nude mice was also studied. We found that Gal-3 expression was not related to age and sex, but positively associated with tumor invasion (P<0.001), tumor sizes (P<0.001) and pre-operative prolactin levels (P<0.001). The multivariate Cox analysis showed that the Gal-3 expression was closely associated with the recurrence of PA after the surgical treatment (HR =3.15, P=0.002). The in vitro studies showed that Gal-3 knock-down by the siRNA technique significantly inhibited the proliferation, migration and invasion ability of the MMQ cells, whereas Gal-3 siRNA transfection induced apoptosis of the MMQ cells. The in vivo tumorgenesis assay showed that Gal-3 siRNA transfection significantly inhibited the tumor volume in vivo compared to transfection of the control siRNA (P<0.001). Gal-3 regulates proliferation, apoptosis, migration and invasion of the MMQ cells. Gal-3 may be used as a tissue marker to evaluate the clinical feature and prognosis of PA patients. |
Author | Min, Weijie Yu, Longyang Yue, Zhijian Dai, Dongwei Wang, Laixing Cao, Yiqun Lu, Qiong Li, Ya'nan |
Author_xml | – sequence: 1 givenname: Dongwei surname: Dai fullname: Dai, Dongwei – sequence: 2 givenname: Ya'nan surname: Li fullname: Li, Ya'nan email: *Zhijian Yue, Department of Neurosurgery, Changhai Hospital,, Second Military Medical University, Shanghai 200433 (China), Tel. +86-021-31161791, Fax +86-021-31161792, E- Mail zhijianyue@sina.cn – sequence: 3 givenname: Qiong surname: Lu fullname: Lu, Qiong – sequence: 4 givenname: Longyang surname: Yu fullname: Yu, Longyang email: *Zhijian Yue, Department of Neurosurgery, Changhai Hospital,, Second Military Medical University, Shanghai 200433 (China), Tel. +86-021-31161791, Fax +86-021-31161792, E- Mail zhijianyue@sina.cn – sequence: 5 givenname: Weijie surname: Min fullname: Min, Weijie – sequence: 6 givenname: Laixing surname: Wang fullname: Wang, Laixing – sequence: 7 givenname: Yiqun surname: Cao fullname: Cao, Yiqun – sequence: 8 givenname: Zhijian surname: Yue fullname: Yue, Zhijian email: *Zhijian Yue, Department of Neurosurgery, Changhai Hospital,, Second Military Medical University, Shanghai 200433 (China), Tel. +86-021-31161791, Fax +86-021-31161792, E- Mail zhijianyue@sina.cn |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24732466$$D View this record in MEDLINE/PubMed |
BookMark | eNptkU1vEzEQhleoiH7AgTtClrjAYam9X_YeS9SWSkFEtJytWXscuWzsYHsl-lf6a3G6IQfUk8fWM89Y854WR847LIq3jH5mrO3PKaV1KzpevyhOWFOxsudcHOWasrYUveDHxWmM9zRfeV-9Ko6rhtdV03UnxeP1xbImq-ATWkcu_2wDxmi9IzaSHzhCQk2SJ4vROqtgJFcIacoM8WbXNYJK1pW3qALmYk1WNk02QXgg36wKHjQ6vwECTmcctVUpEpt2bjWFgE4hAZMwkNsprJ8m3IU8YoMuvS5eGhgjvtmfZ8XPq8u7xddy-f36ZnGxLFVTt6k0nWqZ7hQdNArNQKvdLoxQjPNG0b5hVFe6rxrWtXyojBhMS2FATZGbFnh9VtzMXu3hXm6D3eTvSw9WPj34sJYQklUjSoBm6GuAfuhU9nHBuOhzBGpgBgbRZdfH2bUN_veEMcmNjQrHERz6KUrWVqKuBRMso-_36DRsUB8G_8smA59mIO8xxoDmgDAqd7nLQ-6ZPf-PVTmFlINMAez4bMeHueMXhDWGg3ux-jITcqtNpt49S-0lfwGUL8Uf |
CitedBy_id | crossref_primary_10_3390_genes11030306 crossref_primary_10_1007_s10143_023_02199_7 crossref_primary_10_3389_fphar_2024_1505022 crossref_primary_10_4103_drj_drj_706_23 crossref_primary_10_1111_jne_12352 crossref_primary_10_1007_s11102_015_0674_1 crossref_primary_10_3390_ijms242115719 |
ContentType | Journal Article |
Copyright | 2014 S. Karger AG, Basel 2014 S. Karger AG, Basel. |
Copyright_xml | – notice: 2014 S. Karger AG, Basel – notice: 2014 S. Karger AG, Basel. |
DBID | M-- AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA |
DOI | 10.1159/000358673 |
DatabaseName | Karger Open Access Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: M-- name: Karger Open Access Journals url: https://www.karger.com/OpenAccess sourceTypes: Enrichment Source Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry Biology |
EISSN | 1421-9778 |
EndPage | 1035 |
ExternalDocumentID | oai_doaj_org_article_aa4b93aa9b6c416781789115cb1fab86 24732466 10_1159_000358673 358673 |
Genre | Journal Article |
GroupedDBID | --- 0R~ 0~B 29B 30W 326 36B 3O. 4.4 53G 5GY 5VS 6J9 8UI AAFWJ AAYIC ACGFO ACGFS ADBBV AENEX AEYAO AFPKN AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS BAWUL BCNDV CS3 CYUIP DIK DU5 E0A E3Z EBS EJD EMB EMOBN F5P FB. GROUPED_DOAJ HZ~ IPNFZ KQ8 KUZGX M-- ML- N9A O1H O9- OK1 P2P RIG RKO RNS SV3 UJ6 7X7 88E 8FI 8FJ AAYXX ABBTS ABUWG ABWCG ACQXL ADAGL AFKRA AFSIO AHFRZ AIOBO BENPR BPHCQ BVXVI CAG CCPQU CITATION COF FYUFA HMCUK IAO IHR ITC M1P PHGZM PHGZT PQQKQ PROAC PSQYO RXVBD UKHRP 3V. CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c435t-f6c51d6c0bde8d1adc3586f8c1774c09410d2d9241657b2f8bf50abed0e7f5a73 |
IEDL.DBID | M-- |
ISSN | 1015-8987 1421-9778 |
IngestDate | Wed Aug 27 01:31:15 EDT 2025 Fri Jul 11 02:03:11 EDT 2025 Wed Feb 19 02:35:04 EST 2025 Thu Apr 24 23:07:08 EDT 2025 Tue Jul 01 05:10:44 EDT 2025 Thu Aug 29 12:04:36 EDT 2024 Thu Sep 05 20:30:47 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Pituitary adenomas Prognosis Galectin-3 |
Language | English |
License | Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. 2014 S. Karger AG, Basel. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c435t-f6c51d6c0bde8d1adc3586f8c1774c09410d2d9241657b2f8bf50abed0e7f5a73 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://karger.com/doi/10.1159/000358673 |
PMID | 24732466 |
PQID | 1528338181 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_1528338181 doaj_primary_oai_doaj_org_article_aa4b93aa9b6c416781789115cb1fab86 crossref_primary_10_1159_000358673 crossref_citationtrail_10_1159_000358673 pubmed_primary_24732466 karger_primary_358673 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2014-01-01 |
PublicationDateYYYYMMDD | 2014-01-01 |
PublicationDate_xml | – month: 01 year: 2014 text: 2014-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Basel, Switzerland |
PublicationPlace_xml | – name: Basel, Switzerland – name: Germany |
PublicationTitle | Cellular physiology and biochemistry |
PublicationTitleAlternate | Cell Physiol Biochem |
PublicationYear | 2014 |
Publisher | Cell Physiol Biochem Press GmbH & Co KG |
Publisher_xml | – name: Cell Physiol Biochem Press GmbH & Co KG |
References | Kim YS, Jung JA, Kim HJ, Ahn YH, Yoo JS, Oh S, Cho C, Yoo HS, Ko JH: Galectin-3 binding protein promotes cell motility in colon cancer by stimulating the shedding of protein tyrosine phosphatase kappa by proprotein convertase 5. Biochem Biophys Res Commun 2011;404:96-102.2109413210.1016/j.bbrc.2010.11.071 Asa SL, Ezzat S: The Cytogenesis and Pathogenesis of Pituitary Adenomas. Endocrine Rev 1998;19:798-827.986154610.1210/edrv.19.6.0350 Abucham J, Vieira TC: [Glycoprotein-secreting pituitary adenomas: pathogenesis, diagnosis and treatment]. Arq Bras Endocrinol Metabol 2005;49:657-673.1644434910.1590/S0004-27302005000500007 Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, Hogan V, Raz A: Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer 2010;127:2530-2541.2016256610.1002/ijc.25254 Zhang S, Hou X, Zi S, Wang Y, Chen L, Kong B: Polymorphisms of receptor for advanced glycation end products and risk of epithelial ovarian cancer in Chinese patients. Cell Physiol Biochem 2013;31:525-531.2357122210.1159/000350073 Riss D, Jin L, Qian X, Bayliss J, Scheithauer BW, Young WF, Jr., Vidal S, Kovacs K, Raz A, Lloyd RV: Differential expression of galectin-3 in pituitary tumors. Cancer Res 2003;63:2251-2255.12727847 Gavrilov K, Saltzman WM: Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med 2012;85:187-200.22737048 Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M, Cordon-Cardo C, Sanchez-Carbayo M: Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 2010;31:277-285.2040155810.1007/s13277-010-0033-9 Bergero N, De Pompa R, Sacerdote C, Gasparri G, Volante M, Bussolati G, Papotti M: Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 2005;36:908-914.1611200810.1016/j.humpath.2005.06.020 Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K et al: Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994;76:597-598.812470410.1016/0092-8674(94)90498-7 Raiti S: Pituitary adenomas and other tumors: review in perspective of diagnosis and treatment. Childs Brain 1982;9:147-155.704959810.1159/000120050 Hou X, Hu Z, Huang X, Chen Y, He X, Xu H, Wang N: Serum osteopontin, but not OPN gene polymorphism, is associated with LVH in essential hypertensive patients. J Mol Med (Berl) 2013 [Epub ahead of print].2437094010.1007/s00109-013-1099-9 Honjo Y, Nangia-Makker P, Inohara H, Raz A: Down-Regulation of Galectin-3 Suppresses Tumorigenicity of Human Breast Carcinoma Cells. Clinical Cancer Research 2001;7:661-668.11297262 Huang ZL, Liu HY: [Expression of galectin-3 in liver metastasis of colon cancer and the inhibitory effect of modified citrus pectin]. Nan Fang Yi Ke Da Xue Xue Bao 2008;28:1358-1361.18753060 Huang C, Li M, Chen C, Yao Q: Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 2008;12:637-645.1841024510.1517/14728222.12.5.637 Jin L, Riss D, Ruebel K, Kajita S, Scheithauer BW, Horvath E, Kovacs K, Lloyd RV: Galectin-3 Expression in Functioning and Silent ACTH-Producing Adenomas. Endocr Pathol 2005;16:107-114.1619989510.1385/EP:16:2:107 Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H: Reduced Galectin-3 Expression is an Indicator of Unfavorable Prognosis in Gastric Cancer. Anticancer Res 2006;26:1369-1376.16619546 Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao Y, Feng M, Bao X, Li G, Wang J, Guo K, Ma W, Xing B, Lian W, Xiao J, Cai F, Zhang H, Wang R: Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. Endocrinology 2013;154:1247-1259.2338483610.1210/en.2012-1908 Honjo Y, Inohara H, Akahani S, Yoshii T, Takenaka Y, Yoshida J, Hattori K, Tomiyama Y, Raz A, Kubo T: Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 2000;6:4635-4640.11156213 van den Brule FA, Waltregny D, Liu FT, Castronovo V: Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 2000;89:361-367.1095641110.1002/1097-0215(20000720)89:4<361::AID-IJC8>3.0.CO;2-U Buatti JM, Marcus RB Jr: Pituitary adenomas: current methods of diagnosis and treatment. Oncology 1997;11:791-796.9189937 Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR, Wiseman SM: Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010;176:2067-2081.2036392110.2353/ajpath.2010.090353 Ciric I, Rosenblatt S, Kerr W Jr, Lamarca F, Pierce D, Baumgartner C: Perspective in pituitary adenomas: an end of the century review of tumorigenesis, diagnosis, and treatment. Clin Neurosurg 2000;47:99-111.11197730 Wang SL, Yao HH, Qin ZH: Strategies for short hairpin RNA delivery in cancer gene therapy. Expert Opin Biol Ther 2009;9:1357-1368.1976141710.1517/14712590903236843 Xu XC, el-Naggar AK, Lotan R: Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 1995;147:815-822.7677193 Ochieng J, Fridman R, Nangia-Makker P, Kleiner DE, Liotta LA, Stetler-Stevenson WG, Raz A: Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry 1994;33:14109-14114.794782110.1021/bi00251a020 Asha Das E, Wan-Loo Tan E, Smith DR: Expression of extracellular matrix markers in benign meningiomas. Neuropathology 2003;23:275-281.1471954210.1046/j.1440-1789.2003.00512.x Barondes SH, Cooper DN, Gitt MA, Leffler H: Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994;269:20807-20810.8063692 Hou XW, Son J, Wang Y, Ru YX, Lian Q, Majiti W, Amazouzi A, Zhou YL, Wang PX, Han ZC: Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drugs Ther 2006;20:85-91.1676118910.1007/s10557-006-7652-9 Chanson P, Salenave S: Diagnosis and treatment of pituitary adenomas. Minerva Endocrinol 2004;29:241-275.15765032 Califice S, Castronovo V, Van Den Brule F: Galectin-3 and cancer. Int J Oncol 2004;25:983-992.15375548 Cay T: Immunhistochemical expression of galectin-3 in cancer: a review of the literature. Turk Patoloji Derg 2012;28:1-10.2220742510.5146/tjpath.2012.01090 Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY: Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707-720.864677910.1016/S0092-8674(00)81237-4 Dumont P, Berton A, Nagy N, Sandras F, Tinton S, Demetter P, Mascart F, Allaoui A, Decaestecker C, Salmon I: Expression of galectin-3 in the tumor immune response in colon cancer. Lab Invest 2008;88:896-906.1854204810.1038/labinvest.2008.54 Riss D, Jin L, Qian X, Bayliss J, Scheithauer BW, Young WF, Vidal S, Kovacs K, Raz A, Lloyd RV: Differential Expression of Galectin-3 in Pituitary Tumors. Cancer Research 2003;63:2251-2255.12727847 Moutsatsos IK, Davis JM, Wang JL: Endogenous lectins from cultured cells: subcellular localization of carbohydrate-binding protein 35 in 3T3 fibroblasts. J Cell Biol 1986;102:477-483.351107110.1083/jcb.102.2.477 Hou X, Appleby N, Fuentes T, Longo LD, Bailey LL, Hasaniya N, Kearns-Jonker M: Isolation, Characterization, and Spatial Distribution of Cardiac Progenitor Cells in the Sheep Heart. J Clin Exp Cardiolog 2012;S6:pii:004.2353967510.4172/2155-9880.S6-004 Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996;85:733-744.864678110.1016/S0092-8674(00)81239-8 Righi A, Jin L, Zhang S, Stilling G, Scheithauer BW, Kovacs K, Lloyd RV: Identification and consequences of galectin-3 expression in pituitary tumors. Mol Cell Endocrinol 2010;326:8-14.2045157710.1016/j.mce.2010.04.026 Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim H-RC, Raz A: Galectin-3 Phosphorylation Is Required for Its Anti-apoptotic Function and Cell Cycle Arrest. J Biol Chem 2002;277:6852-6857.1172477710.1074/jbc.M107668200 Kramer MW, Kuczyk MA, Hennenlotter J, Serth J, Schilling D, Stenzl A, Merseburger AS: Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer. Oncol Rep 2008;20:1403-1408.1902072110.3892/or_00000159 Teymoortash A, Pientka A, Schrader C, Tiemann M, Werner J: Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. J Cancer Res Clin Oncol 2006;132:51-56.1618437910.1007/s00432-005-0040-1 Jing M, Li B, Hou X, Shoba J, Li C, Liang H, Zhang X, Liu E, Yang B, Meng X: OPN Gene Polymorphism and the Serum OPN Levels Confer the Susceptibility and Prognosis of Ischemic Stroke in Chinese Patients. Cell Physiol Biochem 2013;32:1798-1807.2435593210.1159/000356613 |
References_xml | – reference: Righi A, Jin L, Zhang S, Stilling G, Scheithauer BW, Kovacs K, Lloyd RV: Identification and consequences of galectin-3 expression in pituitary tumors. Mol Cell Endocrinol 2010;326:8-14.2045157710.1016/j.mce.2010.04.026 – reference: Moutsatsos IK, Davis JM, Wang JL: Endogenous lectins from cultured cells: subcellular localization of carbohydrate-binding protein 35 in 3T3 fibroblasts. J Cell Biol 1986;102:477-483.351107110.1083/jcb.102.2.477 – reference: Zhang S, Hou X, Zi S, Wang Y, Chen L, Kong B: Polymorphisms of receptor for advanced glycation end products and risk of epithelial ovarian cancer in Chinese patients. Cell Physiol Biochem 2013;31:525-531.2357122210.1159/000350073 – reference: Asa SL, Ezzat S: The Cytogenesis and Pathogenesis of Pituitary Adenomas. Endocrine Rev 1998;19:798-827.986154610.1210/edrv.19.6.0350 – reference: Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996;85:733-744.864678110.1016/S0092-8674(00)81239-8 – reference: Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, Hogan V, Raz A: Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer 2010;127:2530-2541.2016256610.1002/ijc.25254 – reference: Ochieng J, Fridman R, Nangia-Makker P, Kleiner DE, Liotta LA, Stetler-Stevenson WG, Raz A: Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry 1994;33:14109-14114.794782110.1021/bi00251a020 – reference: Kim YS, Jung JA, Kim HJ, Ahn YH, Yoo JS, Oh S, Cho C, Yoo HS, Ko JH: Galectin-3 binding protein promotes cell motility in colon cancer by stimulating the shedding of protein tyrosine phosphatase kappa by proprotein convertase 5. Biochem Biophys Res Commun 2011;404:96-102.2109413210.1016/j.bbrc.2010.11.071 – reference: Kramer MW, Kuczyk MA, Hennenlotter J, Serth J, Schilling D, Stenzl A, Merseburger AS: Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer. Oncol Rep 2008;20:1403-1408.1902072110.3892/or_00000159 – reference: Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR, Wiseman SM: Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010;176:2067-2081.2036392110.2353/ajpath.2010.090353 – reference: Ciric I, Rosenblatt S, Kerr W Jr, Lamarca F, Pierce D, Baumgartner C: Perspective in pituitary adenomas: an end of the century review of tumorigenesis, diagnosis, and treatment. Clin Neurosurg 2000;47:99-111.11197730 – reference: Jing M, Li B, Hou X, Shoba J, Li C, Liang H, Zhang X, Liu E, Yang B, Meng X: OPN Gene Polymorphism and the Serum OPN Levels Confer the Susceptibility and Prognosis of Ischemic Stroke in Chinese Patients. Cell Physiol Biochem 2013;32:1798-1807.2435593210.1159/000356613 – reference: Xu XC, el-Naggar AK, Lotan R: Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 1995;147:815-822.7677193 – reference: Jin L, Riss D, Ruebel K, Kajita S, Scheithauer BW, Horvath E, Kovacs K, Lloyd RV: Galectin-3 Expression in Functioning and Silent ACTH-Producing Adenomas. Endocr Pathol 2005;16:107-114.1619989510.1385/EP:16:2:107 – reference: Bergero N, De Pompa R, Sacerdote C, Gasparri G, Volante M, Bussolati G, Papotti M: Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 2005;36:908-914.1611200810.1016/j.humpath.2005.06.020 – reference: Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M, Cordon-Cardo C, Sanchez-Carbayo M: Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 2010;31:277-285.2040155810.1007/s13277-010-0033-9 – reference: Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K et al: Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994;76:597-598.812470410.1016/0092-8674(94)90498-7 – reference: Honjo Y, Inohara H, Akahani S, Yoshii T, Takenaka Y, Yoshida J, Hattori K, Tomiyama Y, Raz A, Kubo T: Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 2000;6:4635-4640.11156213 – reference: Huang C, Li M, Chen C, Yao Q: Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 2008;12:637-645.1841024510.1517/14728222.12.5.637 – reference: Asha Das E, Wan-Loo Tan E, Smith DR: Expression of extracellular matrix markers in benign meningiomas. Neuropathology 2003;23:275-281.1471954210.1046/j.1440-1789.2003.00512.x – reference: Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao Y, Feng M, Bao X, Li G, Wang J, Guo K, Ma W, Xing B, Lian W, Xiao J, Cai F, Zhang H, Wang R: Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. Endocrinology 2013;154:1247-1259.2338483610.1210/en.2012-1908 – reference: Barondes SH, Cooper DN, Gitt MA, Leffler H: Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994;269:20807-20810.8063692 – reference: Buatti JM, Marcus RB Jr: Pituitary adenomas: current methods of diagnosis and treatment. Oncology 1997;11:791-796.9189937 – reference: Huang ZL, Liu HY: [Expression of galectin-3 in liver metastasis of colon cancer and the inhibitory effect of modified citrus pectin]. Nan Fang Yi Ke Da Xue Xue Bao 2008;28:1358-1361.18753060 – reference: Teymoortash A, Pientka A, Schrader C, Tiemann M, Werner J: Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. J Cancer Res Clin Oncol 2006;132:51-56.1618437910.1007/s00432-005-0040-1 – reference: Hou X, Hu Z, Huang X, Chen Y, He X, Xu H, Wang N: Serum osteopontin, but not OPN gene polymorphism, is associated with LVH in essential hypertensive patients. J Mol Med (Berl) 2013 [Epub ahead of print].2437094010.1007/s00109-013-1099-9 – reference: Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim H-RC, Raz A: Galectin-3 Phosphorylation Is Required for Its Anti-apoptotic Function and Cell Cycle Arrest. J Biol Chem 2002;277:6852-6857.1172477710.1074/jbc.M107668200 – reference: Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H: Reduced Galectin-3 Expression is an Indicator of Unfavorable Prognosis in Gastric Cancer. Anticancer Res 2006;26:1369-1376.16619546 – reference: Honjo Y, Nangia-Makker P, Inohara H, Raz A: Down-Regulation of Galectin-3 Suppresses Tumorigenicity of Human Breast Carcinoma Cells. Clinical Cancer Research 2001;7:661-668.11297262 – reference: Gavrilov K, Saltzman WM: Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med 2012;85:187-200.22737048 – reference: Riss D, Jin L, Qian X, Bayliss J, Scheithauer BW, Young WF, Jr., Vidal S, Kovacs K, Raz A, Lloyd RV: Differential expression of galectin-3 in pituitary tumors. Cancer Res 2003;63:2251-2255.12727847 – reference: Cay T: Immunhistochemical expression of galectin-3 in cancer: a review of the literature. Turk Patoloji Derg 2012;28:1-10.2220742510.5146/tjpath.2012.01090 – reference: Riss D, Jin L, Qian X, Bayliss J, Scheithauer BW, Young WF, Vidal S, Kovacs K, Raz A, Lloyd RV: Differential Expression of Galectin-3 in Pituitary Tumors. Cancer Research 2003;63:2251-2255.12727847 – reference: Raiti S: Pituitary adenomas and other tumors: review in perspective of diagnosis and treatment. Childs Brain 1982;9:147-155.704959810.1159/000120050 – reference: van den Brule FA, Waltregny D, Liu FT, Castronovo V: Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 2000;89:361-367.1095641110.1002/1097-0215(20000720)89:4<361::AID-IJC8>3.0.CO;2-U – reference: Dumont P, Berton A, Nagy N, Sandras F, Tinton S, Demetter P, Mascart F, Allaoui A, Decaestecker C, Salmon I: Expression of galectin-3 in the tumor immune response in colon cancer. Lab Invest 2008;88:896-906.1854204810.1038/labinvest.2008.54 – reference: Abucham J, Vieira TC: [Glycoprotein-secreting pituitary adenomas: pathogenesis, diagnosis and treatment]. Arq Bras Endocrinol Metabol 2005;49:657-673.1644434910.1590/S0004-27302005000500007 – reference: Wang SL, Yao HH, Qin ZH: Strategies for short hairpin RNA delivery in cancer gene therapy. Expert Opin Biol Ther 2009;9:1357-1368.1976141710.1517/14712590903236843 – reference: Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY: Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707-720.864677910.1016/S0092-8674(00)81237-4 – reference: Hou XW, Son J, Wang Y, Ru YX, Lian Q, Majiti W, Amazouzi A, Zhou YL, Wang PX, Han ZC: Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drugs Ther 2006;20:85-91.1676118910.1007/s10557-006-7652-9 – reference: Califice S, Castronovo V, Van Den Brule F: Galectin-3 and cancer. Int J Oncol 2004;25:983-992.15375548 – reference: Hou X, Appleby N, Fuentes T, Longo LD, Bailey LL, Hasaniya N, Kearns-Jonker M: Isolation, Characterization, and Spatial Distribution of Cardiac Progenitor Cells in the Sheep Heart. J Clin Exp Cardiolog 2012;S6:pii:004.2353967510.4172/2155-9880.S6-004 – reference: Chanson P, Salenave S: Diagnosis and treatment of pituitary adenomas. Minerva Endocrinol 2004;29:241-275.15765032 |
SSID | ssj0015792 |
Score | 2.0574076 |
Snippet | Background: Previous in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of... Previous in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of Gal-3 expression... |
SourceID | doaj proquest pubmed crossref karger |
SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1026 |
SubjectTerms | Adult Animals Apoptosis Carcinogenesis Cell Line, Tumor Cell Movement Cell Proliferation Female Galectin 3 - antagonists & inhibitors Galectin 3 - genetics Galectin 3 - metabolism Galectin-3 Humans Immunohistochemistry Male Mice Mice, Nude Middle Aged Original Paper Pituitary adenomas Pituitary Neoplasms - metabolism Pituitary Neoplasms - pathology Pituitary Neoplasms - surgery Prognosis Prolactin - metabolism Recurrence RNA, Small Interfering - metabolism Transplantation, Heterologous |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pa9VAEF6kIHoRrVVjq6ziwUtoNsnu5h3bR2sRKw_aQm9hf0LwNSnvJWD_Ff_azuwmQUXx4jWZLMvO7M43mdlvCPmgS-FtyWyae4lXcoRLNVMszY0ucqsFV-GG3PlXcXZVfr7m1z-1-sKasEgPHBfuUKlSLwqlFloYAA-yYrKCDcqNZl7pKpBtg8-bgqkxf8DlIuY5GU8rCKtHTiHw3YcheVYJWfziiQJhP3ihb1h_vfk73Axu5_QpeTLiRXoU5_mMPHDtLnkYO0je7ZJHy6lh23Py49PRl4KukHihaenJ97HEtaXNloaaN2dp39GRCXRNEf0NIEM7j1-t8YpDm14gjsRaaLpq-qHp1eaOnmPVnoITqrtRVLUWxDG_029p0-PYJpA8GUdDx3F6MWzCeUovpyr2PXJ1enK5PEvH1gupAfzUp14YzqwwmbauskxZg2vmK8MALhoICVlmcwuxGxNc6txX2vNMaWczJz1XsnhBdtquda8IzXwuVQ7IRwtZQviiBSCK0sFh4LVxVZmQj5MaajPykmN7jHUd4hO-qGeNJeT9LHobyTj-JHSMupwFkD87PACrqkerqv9lVQnZi5YwDzMNfvDb8-XqOL6qb61PyLvJbmpQPuZeVOu6YVszJNFBdMQS8jIa1DxEXkqAtUK8_h8z3yePAdOV8S_RAdnpN4N7A7ip12_DFrkHlGUTfw priority: 102 providerName: Directory of Open Access Journals |
Title | GAL3 Protein Expression is Related to Clinical Features of Prolactin-Secreting Pituitary Microadenoma and Predicts its Recurrence after Surgical Treatment |
URI | https://karger.com/doi/10.1159/000358673 https://www.ncbi.nlm.nih.gov/pubmed/24732466 https://www.proquest.com/docview/1528338181 https://doaj.org/article/aa4b93aa9b6c416781789115cb1fab86 |
Volume | 33 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Lb9QwELagCNELglIgUCqDOHCxWCexnT22q5YKsWiltlJvkZ9VxJJUu4nU_hV-LTPOA4Ho1RnbisePbzzjbwj5aHIZXM4dS4PCJznSM8M1Z6k1WeqMFDq-kFt-l2eX-dcrcTXcd-BbmB8Y_xypUSduAThwP0ePVyFV9pA8Ajsqw-C9JWOTv0Coee_X5IIVYEYPHEJ_VUXe31wBgIiMiH8OocjVDwdQ3_X9SDOeOKfPyNMBKtKjXrfPyQNf75HHffLIuz3yZDHmantBfn05-pbRFXIuVDU9uR2iW2tabWkMd_OOtg0dSEDXFIFfBzK0CVhrja8banaOEBLDoOmqaruq1Zs7usSAPQ2bU_NTU107EEfXTrulVYtt28jvZD2NycbpebeJWym9GAPY98nl6cnF4owNWReYhXFtWZBWcCftzDhfOK6dxeELheWAFC1Yg3zmUgdmG5dCmTQUJoiZNt7NvApCq-wl2amb2r8mdBZSpVMAPUaqHCwXIwFM5B72gWCsL_KEfBrVUNqBkhwzY6zLaJqIeTkpLyEfJtGbnofjf0LHqMtJAKmzY0GzuS6HlVhqnZt5pvXcSAv_oAquCtjxhTU8aFPIhOz3M2FqZmz84J_yxeq4_1TeuJCQ9-O8KUH56HbRtW-6bcmRPweBEU_Iq35CTU2ME_LNPZ2-JbuA0PL-zueA7LSbzr8DFNSaw3h7cBiXwW8EqgBy |
linkProvider | Karger AG |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Lb9QwELagCJULglIgUMAgDlws4iS2k2O7allgt1qpW6m3yE8UsSTVbiLRv8KvxeM8EIhek7GtZPz4xjPzDULvVcadyaghiROQksMtUVRSkmiVJkZxJkOG3PKczy-zL1fsarjvgFyY7xD_HKhRJ24Bf-B-DB6vnIv0LronCl4AS_6SkMlfwETR-zUpI7k3owcOob-aAu9vJjyACIyIfw6hwNXvD6B-6NuRZjhxzh6hhwNUxMe9bh-jO7Y-QPf74pE3B2h_NtZqe4J-fTpepHgFnAtVjU9_DtGtNa52OIS7WYPbBg8koBsMwK_zMrhx0GoD2Q01uQAICWHQeFW1XdXK7Q1eQsCe9JtT80NiWRsvDq6ddoerFvrWgd9JWxyKjeOLbhu2UrweA9gP0eXZ6Xo2J0PVBaI9dGqJ45pRw3WsjM0NlUbD73O5ph4pam8N0tgkxpttlDOhEpcrx2KprImtcEyK9Cnaq5vaPkc4domQiQc9iovMWy6KezCRWb8POKVtnkXow6iGUg-U5FAZY1MG04QV5aS8CL2bRK97Ho7_CZ2ALicBoM4OD5rtt3JYiaWUmSpSKQvFtf8GkVOR-x2faUWdVDmP0GE_E6Zuxs6P_nk-W530r8pr4yL0dpw3pVc-uF1kbZtuV1LgzwFgRCP0rJ9QUxfjhHxxy6Bv0P58vVyUi8_nX1-iBx6tZf39zxHaa7edfeURUateh8XwG0z9AnU |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=GAL3+protein+expression+is+related+to+clinical+features+of+prolactin-secreting+pituitary+microadenoma+and+predicts+its+recurrence+after+surgical+treatment&rft.jtitle=Cellular+physiology+and+biochemistry&rft.au=Dai%2C+Dongwei&rft.au=Li%2C+Ya%27nan&rft.au=Lu%2C+Qiong&rft.au=Yu%2C+Longyang&rft.date=2014-01-01&rft.eissn=1421-9778&rft.volume=33&rft.issue=4&rft.spage=1026&rft_id=info:doi/10.1159%2F000358673&rft_id=info%3Apmid%2F24732466&rft.externalDocID=24732466 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1015-8987&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1015-8987&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1015-8987&client=summon |